Sentence examples for cost-effectiveness benchmarks from inspiring English sources

In economic terms, capecitabine would be termed a 'dominant' (cost saving and more effective) treatment strategy, taking its place among other cost-effectiveness benchmarks in oncology (Table 6).

In concentrated epidemics where HIV prevalence in the general population is very low, MTCT strategies based on universal testing of pregnant women may not compare well against cost-effectiveness benchmarks, or may satisfy formal criteria for cost-effectiveness but offer a low relative value as compared to competing interventions to improve population health.

In concentrated epidemics where HIV prevalence in the general population is low, MTCT strategies based on universal or targeted testing of pregnant women may not compare well against cost-effectiveness benchmarks, or may satisfy formal criteria for cost-effectiveness but offer a low relative value in relation to competing interventions to improve population health.

The remaining studies either used ulcer-free weeks or months (or calculations were made in these units) or progressively more obscure effectiveness units, which meant that most of the ICERs or INHBs could not easily be related to any other health economic studies in wound care nor easily assessed against any common cost-effectiveness benchmarks.

Clinical guidelines, cost-effectiveness and benchmarking data achieved only 50% importance rating.

Although the standard approach in cost-effectiveness analysis relies on benchmarks for high-value interventions using the same threshold value for the WTP per QALY for all interventions, we observe substantial differences in the WTP per QALY to avoid different health states.

The WTP value represents the benchmark cost-effectiveness for assessing combinations of supplement costs and relative reductions in survival and/or loss to follow-up.

The WTP values, or the benchmark cost-effectiveness of standard ART treatment against which alternate interventions can be compared, were $853.31, $847.53, and $845.87 per DALY averted in the BMI <16.0, 16.00-16.99, and 17.00-18.49 kg/m categories, respectively.

Services are also very cost-effective, achieving an average cost per life year saved, after allowance for future health care savings, of £438 [ 2], which is over 50 times below the English National Institute of Health and Clinical Excellence's benchmark cost-effectiveness figure of £30,000 [ 3].

This model-based analysis indicates that nebivolol is highly cost-effective, achieving an incremental cost-effectiveness ratio well below a standard benchmark used for resource allocation decisions in elderly people with heart failure, when compared to standard medical therapy.

Conventional benchmarks of cost-effectiveness are typically set at 50,000 USD/QALY (35), although this threshold has been questioned and benchmarks of 109,000 297,000 USD/QALY may be more reflective of actual U.S. resource-allocation decisions (36).